Clinical trials: Hematological Neoplasm
Hematological Malignancy, Leukemia
Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients
The aim of this study is to compare the efficacy and tolerance of piperacillin-tazobactam versus piperacillin-tazobactam plus glycopeptide as initial empiric antibiotic treatment for fever in neutropenic patients.
- Conditions
- Hematological Malignancy, Leukemia, Myelodysplasia, Lymphoma
- Trial name
- NCT00195533
- Testing
- piperacillin-tazobactam, glycopeptide
- Where
- 12 sites in Spain
- Volunteers
- 801 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Advanced Cancer
A Trial of ZL-1201 in Subjects With Advanced Cancer
First in Human, Phase I Trial of ZL-1201 in Subjects with Advanced Cancer
- Trial name
- NCT04257617
- Testing
- ZL-1201
- Where
- 7 sites in United States, China
- Volunteers
- 37 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
The purpose of this study is to evaluate the safety and efficacy of CAR T cell treatment targeting TRBC1 in patients with relapsed or refractory TRBC1 positive T-cell hematological maliganacies
- Conditions
- Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Lymphoma, Acute T Cell Leukemia
- Trial name
- NCT04828174
- Testing
- anti-TRBC1 CAR-T cell therapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
This phase II MATCH treatment trial identifies the effects of trametinib in patients whose cancer has a has a genetic change called NF1 mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439318
- Testing
- Trametinib Dimethyl Sulfoxide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
This phase I/II trial studies the side effects and the best dose of inotuzumab ozogamicin when given together with fludarabine phosphate, bendamustine hydrochloride, and rituximab before donor stem cell transplant in treating…
- Trial name
- NCT01664910
- Testing
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors and Hematologic Malignancy
Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors
To establish the maximum tolerated dose (MTD) of INCB007839 given as multiple doses for 28 days and to determine if a higher MTD can be established when INCB007839 is administered in combination with prophylactic anticoagulation…
- Trial name
- NCT00820560
- Testing
- INCB007839
- Where
- 4 sites in United States
- Volunteers
- 41 people
- Sponsor
- Incyte Corporation
Multiple Myeloma, Primary Plasma Cell Leukemia
Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia.
- Trial name
- NCT06333509
- Testing
- CT071
- Volunteers
- 166 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Carbapenem-resistant Enterobacterales, Neutropenia
Prospective Study Evaluate the Timing of Empirical Treatment for Carbapenem-resistant Bacterials (CROEAT Study)
In this study, we will evaluate the feasibility and clinical outcomes of risk adaptive empirical therapy to cover carbapenem resistance gram negative bacteria (CRO) in patients with hematological malignancies colonized with CRO.
- Conditions
- Carbapenem-resistant Enterobacterales, Neutropenia, Hematological Malignancies
- Trial name
- NCT07047352
- Testing
- Empirical treatment
- Where
- China
- Volunteers
- 91 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Hematologic Malignancies
Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation
This is a randomized trial for patients undergoing hematopoietic progenitor cell transplantation (HPCT) from an unrelated donor.
- Trial name
- NCT01217723
- Testing
- Anti-Thymocyte Globulin (Rabbit), Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin)
- Where
- 10 sites in Canada
- Volunteers
- 198 people
- Sponsor
- McMaster University
Allogeneic Stem Cell Transplantation
A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation
To learn if ASTX727 given alone or in combination with donor lymphocyte infusion (DLI) can help to control certain types of hematological neoplasms (blood-based cancers) after a stem cell transplant.
- Trial name
- NCT06297629
- Testing
- ASTX727, Donor Lymphocyte Infusion
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Malignancy
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
The purpose of this research study is to examine the survival of patients undergoing partially matched hematopoietic stem cell transplant (HSCT) on a new type of treatment approach, which has been developed specifically for…
- Trial name
- NCT01341301
- Testing
- Total Body Irradiation, Donor Lymphocyte Infusion (DLI), Cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Malignant Solid Tumour, Hematologic Malignancies
Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation
The primary objective of this study is to assess the feasibility of a multi-institutional study that collects cardiopulmonary exercise testing and 6 minute walk distance performance testing prior to a cycle of chemotherapy (or…
- Conditions
- Malignant Solid Tumour, Hematologic Malignancies, Planned Hematopoietic Cell Transplantation
- Trial name
- NCT02786628
- Testing
- Physical performance testing and patient-generated health data
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Malignant Solid Neoplasm, Hematopoietic Neoplasms
Optimizing Health Related Quality of Life Measurement in Adolescent and Young Adult Oncology
This study evaluates how adolescent and young adults with cancer in the U.S. and their loved ones respond to questions that will later be used with people who may have cancer and other chronic health conditions
- Conditions
- Malignant Solid Neoplasm, Hematopoietic Neoplasms, Lymphatic System Neoplasm
- Trial name
- NCT06897137
- Testing
- Surveys/Questionnaires
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Hematologic Neoplasms
Impact of Pulmonary Follow-up After Stem Cell Graft
Allogeneic hematopoietic stem cell transplantation is the only possible treatment for many malignant and non-malignant hemopathies.
- Trial name
- NCT03349372
- Testing
- Hematopoietic stem cell transplantation
- Where
- France
- Volunteers
- 227 people
- Sponsor
- Hospices Civils de Lyon
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study
This trial studies how well an interactive survivorship program works in improving healthcare resources in adolescent and young adult cancer survivors.
- Conditions
- Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- NCT04593277
- Testing
- Internet Mobile Technology, Internet-Based Intervention, Questionnaire Administration
- Where
- 5 sites in United States
- Volunteers
- 549 people
- Sponsor
- Fred Hutchinson Cancer Center
Relapsed or Refractory Multiple Myeloma
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-06 and to characterize the safety and tolerability of EMB-06 at the RP2Ds.
- Trial name
- NCT04735575
- Testing
- EMB-06
- Where
- 10 sites in Australia, China
- Volunteers
- 40 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Adult Relapsed/Refractory B-cell Hematologic Malignancies
CAR-NK Targeted CD19 for r/r B-cell Malignancies
This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of JD010 in adult patients with relapsed or refractory B cell hematologic malignancies.
- Trial name
- NCT05645601
- Testing
- CD19-CAR-NK
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Hematological Malignancies
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
To determine the safety and efficacy (1-year PFS) of iC9/CD5CAR/IL-15 NK cells as consolidation in patients with aggressive T-cell malignances in first remission.
- Trial name
- NCT07137481
- Testing
- C9/CD5CAR/IL-15 NK cells, Rituximab, Fludarabine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Myelofibrosis, Leukemia, Myelocytic, Acute
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Phase 1 Part: This was an open-label, sequential dose escalation study of pelabresib (CPI-0610) in patients who had previously been treated for Acute Leukemia, Myelodysplastic/Myeloproliferative Neoplasms.
- Conditions
- Myelofibrosis, Leukemia, Myelocytic, Acute, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic Syndrome (MDS)
- Trial name
- NCT02158858
- Testing
- Pelabresib, Ruxolitinib
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 336 people
- Sponsor
- Constellation Pharmaceuticals
Coronavirus Disease 2019 (Covid19), Hematopoietic Neoplasms
Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)
The present study is a prospective phase IV study. All participants will receive the anti-Coronavirus Disease 2019 (COVID-19) Vaccine (messenger Ribonucleic acid-based vaccine, BNT162b2 or Comirnaty®, commercialized by…
- Trial name
- NCT04951323
- Testing
- anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Liege
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.